Equities

CSMED

DK0061668225

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
7.043 ^DKK	+12.63%		+2.38%	+50.40%

04-30	CS Medica A/S Enters New Partnership with OTC Company Holding A Strong Position in the Chronic Pain Segment in Germany	CI
04-22	CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy	CI

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

April 04, 2024 at 08:01 am

CS MEDICA announced the Malaysian approval of CANNASEN Protective Nasal Gel. This important approval not only brings an innovative product to the market but symbolizes CS MEDICA's breakthrough in overcoming the complex regulatory barriers in Asia. CS MEDICA is positioned to leverage the momentum to expand its product range throughout Asia.

The insights gained and the strategies developed through this process are key to smoothing the pathway for futurerations, especially towards markets such as China.

Latest news about CS MEDICA A/S

CS Medica A/S Enters New Partnership with OTC Company Holding A Strong Position in the Chronic Pain Segment in Germany	04-30	CI
CS Medica A/S Advances Global Reach with 180° Drug Store Alliance, Powered by Pull Market Strategy	04-22	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Apr 12, 2024	04-12
CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia	04-04	CI
Transcript : CS Medica A/S, 2023 Earnings Call, Feb 21, 2024	02-21
CS MEDICA A/S Partners with New Distributor to Launch CANNASEN into Jordan	02-20	CI
CS Medica Obtains Danish Patent for Wound Healing Gel	02-02	MT
CS Medica Set to Launch Pain Patch, Cosmetic Products in Australia	01-26	MT
CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market	12-27	CI
Transcript : CS Medica A/S, Q4 2023 Earnings Call, Dec 05, 2023	12-05
CS Medica A/S Announces Financial Year Change	11-22	CI
CS Medica A/S Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	11-22	CI
CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2023	11-22	CI
CS Medica's Nasal Protect Gel Secures Second Patent in Denmark	23-10-31	MT
Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products	23-10-12	CI
Danske Bank Extends DKK 1.2 Million Credit Line to CS MEDICA	23-10-10	CI
CS Medica A/S Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-09-13	CI
CS Medica Secures Denmark Patent for Nasal Spray	23-08-30	MT
Transcript : CS Medica A/S, Q3 2023 Earnings Call, Aug 08, 2023	23-08-08
CS MEDICA A/S Announces Establishment of CANNORDIC India Pvt. Ltd. to Expand Presence in India	23-07-14	CI
CS Medica A/S Signs New Own-Label Agreement on Pain Patch	23-06-21	CI
CS Medica Signs Deal for Future Compliance for CE-marked Medical Devices with CBD in EU	23-06-15	MT
CS MEDICA A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body	23-06-15	CI
CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body	23-06-15	CI
CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis	23-05-08	CI

Chart CS MEDICA A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar